Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Analytical Chemistry

High-Resolution Mass Spec Of Individual Embryonic Cells

Proteomics: Individual cells from frog embryos have overlapping but widely different proteomes

by Celia Henry Arnaud
January 25, 2016 | A version of this story appeared in Volume 94, Issue 4

Most proteomic analyses are averages of many cells. But as the sensitivity of mass spectrometry improves, comprehensive analysis of individual cells is becoming possible. By combining single-cell capillary electrophoresis, microflow electrospray ionization, and high-resolution mass spectrometry, Peter Nemes, Sally A. Moody, and Camille Lombard-Banek of George Washington University have performed proteomic analyses of individual cells dissected from a 16-cell frog embryo (Angew. Chem. Int. Ed. 2016, DOI: 10.1002/anie.201510411). The researchers extracted and identified a total of 1,709 different proteins from three types of cells destined to develop into different parts of the frog’s body. To quantify proteins with high sensitivity, they used different mass tags to label each cell’s proteome, allowing them to detect even trace-level proteins at a low nanomolar concentration. Nearly a quarter of the proteins were common to all three cell types, but each cell type also had several hundred proteins unique to it. With the more direct measurements, the researchers were able to observe differences in protein expression that indicate dorsal-ventral asymmetry is already established, even at this early stage of development.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.